Ann Thorac Surg 2003;76:1992
© 2003 The Society of Thoracic Surgeons
Invited commentary
Jan T. Christenson, MA, MD
Clinic for Cardiovascular Surgery, University Hospital of Geneva, 24, rue Micheli-du-Crest, CH-1211 Geneva 14, Switzerland
e-mail: jan.christenson@hcuge.ch
| The first 20% of the full text of this article appears below. |
Intraaortic balloon counterpulsation (IABC), introduced in the 60's, still remains the mainstay therapy for patients with postcardiotomy heart failure and acute coronary syndromes. Cardiogenic shock and recurrent intractable arrhythmia have long been regarded as clear indications for IABC use. Signs of hemodynamic instability, poor LV function, or persistent asymptomatic or symptomatic ischemia in patients with large areas of myocardium at risk have been added to the list of indications. During recent years, an enlightened, proactive approach . . . [Full Text of this Article]
Copyright © 2003 by The Society of Thoracic Surgeons.